{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:06:51Z","timestamp":1790208411259,"version":"4.1.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>To determine the agreement between the PSMA-RADS and E-PSMA standardized reporting systems in the classification of [<jats:sup>18<\/jats:sup>F]PSMA-1007\u2013uptaking lesions identified on PET\/CT scan in patients with prostate cancer (PCa) and post-prostatectomy with suspected recurrent disease (local recurrence, regional nodal involvement and distant metastases), based on biochemical recurrence, while also exploring the correlation between lesion size and tracer uptake.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>A retrospective cross-sectional study of 32 post-prostatectomy PCa patients who had suspected recurrent disease based on biochemical recurrence post-prostatectomy (prostate-specific antigen values that are 0.2\u2009ng\/mL or higher) underwent [<jats:sup>18<\/jats:sup>F]PSMA-1007 PET\/CT scan. The recurrent disease PCa lesions were characterized and subsequently classified using two standardized reporting systems (PSMA-RADS and E-PSMA). The lesions were grouped based on anatomical site, their size and SUVmax were compared using Kruskal-Wallis test with Dunn-Bonferroni <jats:italic>post hoc<\/jats:italic> tests. Spearman correlation coefficients were calculated between the size of the lesions and their SUVmax of the radiotracer [<jats:sup>18<\/jats:sup>F]PSMA-1007 for all the lesions and when grouped by anatomical site. Additionally, the agreement between lesion classifications was assessed using Cohen\u2019s kappa index.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Only 32 (69.98\u2009\u00b1\u20098.27, men) patients met the inclusion criteria, a total of 149 lesions with avid uptake of [<jats:sup>18<\/jats:sup>F]PSMA-1007 were identified. Positive correlation (<jats:italic>r<\/jats:italic>\u2009=\u20090.516, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001) was observed between the size of the metastatic prostate cancer lymph node lesions and their [<jats:sup>18<\/jats:sup>F]PSMA-1007 uptake. Substantial agreement was noted between the PSMA-RADS and E-PSMA classification system scores among all lesions (\u03ba\u2009=\u20090.70, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001), with notable discrepancies primarily among lymph node lesions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings revealed a positive correlation between the size of the metastatic prostate cancer lymph node lesions and [<jats:sup>18<\/jats:sup>F]PSMA-1007 uptake, and although there was substantial agreement between the PSMA-RADS and E-PSMA classification systems, there were discrepancies mainly among the lymph node lesions.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1368093","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T04:39:15Z","timestamp":1710218355000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Agreement between PSMA-RADS and E-PSMA systems in classifying [18F]PSMA-1007 PET\/CT lesions among prostate cancer patients: exploring the correlation between lesion size and uptake"],"prefix":"10.3389","volume":"11","author":[{"given":"Miguel","family":"Mendoza-\u00c1vila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiram","family":"Esparza-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Andr\u00e9s","family":"Castillo-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edel Rafael","family":"Rodea-Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study","volume":"3","author":"Fitzmaurice","year":"2017","journal-title":"JAMA Oncol"},{"key":"ref2","first-page":"927","article-title":"Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients","volume":"7","author":"Horoszewicz","year":"1987","journal-title":"Anticancer Res"},{"key":"ref3","first-page":"227","article-title":"Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen","volume":"53","author":"Israeli","year":"1993","journal-title":"Cancer Res"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2967\/JNUMED.121.262997","article-title":"The history of prostate-specific membrane antigen as a Theranostic target in prostate Cancer: the cornerstone role of the Prostate Cancer Foundation","volume":"63","author":"Miyahira","year":"2022","journal-title":"J Nucl Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1148\/RADIOL.2021202771","article-title":"Prostate-specific membrane antigen PET in prostate cancer","volume":"299","author":"Lawhn-Heath","year":"2021","journal-title":"Radiology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.urolonc.2013.09.003","article-title":"The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research","volume":"32","author":"Ristau","year":"2014","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1158\/1078-0432.CCR-04-2690","article-title":"Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer","volume":"11","author":"Foss","year":"2005","journal-title":"Clin Cancer Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph13010012","article-title":"Current status of PSMA-radiotracers for prostate cancer: data analysis of prospective trials listed on clinicaltrials.gov","volume":"13","author":"Zippel","year":"2020","journal-title":"Pharmaceuticals"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/3502389","article-title":"18F-PSMA-1007 PET in biochemical recurrent prostate Cancer: an updated Meta-analysis","volume":"2021","author":"Ferrari","year":"2021","journal-title":"Contrast Media Mol Imaging"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.eururo.2007.04.020","article-title":"Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy{a figure is presented}","volume":"52","author":"Heidenreich","year":"2007","journal-title":"Eur Urol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s11307-015-0850-8","article-title":"Initial evaluation of [18F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate Cancer","volume":"17","author":"Szabo","year":"2015","journal-title":"Mol Imaging Biol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers11050710","article-title":"Detection rate of18 F-labeled PSMA PET\/CT in biochemical recurrent prostate cancer: a systematic review and a meta-analysis","volume":"11","author":"Treglia","year":"2019","journal-title":"Cancers (Basel)"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/s00345-020-03490-8","article-title":"Detection of prostate cancer with 18F-DCFPyL PET\/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible?","volume":"39","author":"Bodar","year":"2021","journal-title":"The DeTeCT trial World J Urol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","article-title":"F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients","volume":"44","author":"Giesel","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0001-2998(98)80027-5","article-title":"A brief history of positron emission tomography (PET)","volume":"28","author":"Wagner","year":"1998","journal-title":"Semin Nucl Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2967\/jnumed.117.195255","article-title":"Proposal for a structured reporting system for prostate-specific membrane antigen-targeted PET imaging: PSMA-RADS version 1.0","volume":"59","author":"Rowe","year":"2018","journal-title":"J Nucl Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","article-title":"E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET","volume":"48","author":"Ceci","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.juro.2006.10.097","article-title":"Variation in the definition of biochemical recurrence in patients treated for localized prostate Cancer: the American urological association prostate guidelines for localized prostate Cancer update panel report and recommendations for a standard in the re","volume":"177","author":"Cookson","year":"2007","journal-title":"J Urol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1200\/edbk_351033","article-title":"Best approaches and updates for prostate Cancer biochemical recurrence","volume":"42","author":"Simon","year":"2022","journal-title":"Am Soc Clin Oncol Educ B"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate Cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol"},{"key":"ref21","unstructured":"2019"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement of categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1053\/j.semnuclmed.2023.02.006","article-title":"Histopathologically validated diagnostic accuracy of PSMA-PET\/CT in the primary and secondary staging of prostate Cancer and the impact of PSMA-PET\/CT on clinical management: a systematic review and Meta-analysis","volume":"53","author":"Jeet","year":"2023","journal-title":"Semin Nucl Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2020.585213","article-title":"Intra-individual comparison of 18F-PSMA-1007 and 18F-FDG PET\/CT in the evaluation of patients with prostate Cancer","volume":"10","author":"Zhou","year":"2021","journal-title":"Front Oncol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41391-019-0194-6","article-title":"Diagnostic performance of 18F-PSMA-1007 PET\/CT in biochemically relapsed patients with prostate cancer with PSA levels \u2264 2.0 ng\/ml","volume":"23","author":"Witkowska-Patena","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s00330-023-10083-7","article-title":"Reliability and practicability of PSMA-RADS 1.0 for structured reporting of PSMA-PET\/CT scans in prostate cancer patients","volume":"34","author":"Grawe","year":"2023","journal-title":"Eur Radiol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fsurg.2022.943760","article-title":"False positive findings of [18F]PSMA-1007 PET\/CT in patients after radical prostatectomy with undetectable serum PSA levels","volume":"9","author":"Orevi","year":"2022","journal-title":"Front Surg"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s00259-017-3780-7","article-title":"Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging","volume":"44","author":"Sheikhbahaei","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40644-023-00627-x","article-title":"Evaluating the value of 18 F - PSMA - 1007 PET \/ CT in the detection and identification of prostate cancer using histopathology as the standard","volume":"23","author":"Luo","year":"2023","journal-title":"Cancer Imaging"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3390\/cancers15143707","article-title":"Characterization of lymph node tumor burden in node-positive prostate cancer patients after robotic-assisted radical prostatectomy with extended pelvic lymph node dissection","volume":"15","author":"Gottlieb","year":"2023"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ejca.2008.10.028","article-title":"Evaluation of lymph nodes with RECIST 1.1","volume":"45","author":"Schwartz","year":"2009","journal-title":"Eur J Cancer"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate Cancer clinical trials working group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.crad.2007.05.022","article-title":"The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis","volume":"63","author":"H\u00f6vels","year":"2008","journal-title":"Clin Radiol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jimaging7020034","article-title":"Radiomics and prostate MRI: current role and future applications","volume":"7","author":"Cutaia","year":"2021","journal-title":"J Imaging"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1368093\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T04:39:18Z","timestamp":1710218358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1368093\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":34,"alternative-id":["10.3389\/fmed.2024.1368093"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1368093","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,12]]},"article-number":"1368093"}}